This study is testing a new medicine, NNC6989-0001, to test it is safe and tolerable for healthy people living with overweight or obesity. NNC6989-0001 is still being tested in studies and is not yet available for prescription by doctors. In this study, participants will receive either NNC6989-0001 or a placebo; which treatment each participant receives will be decided by chance.
Age range
18 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of treatment emergent adverse events (TEAE) - Part A
Timeframe: From time of dosing on Day1 until completion of the end of study visit (Day 7)
Number of treatment emergent adverse events (TEAE) - Part B
Timeframe: From time of dosing on Day 1 until completion of the end of study visit (Day 14)
iAUCTG; The incremental area under the blood triglycerides concentration-time curve following meal test - Part C
Timeframe: Following meal test at Day -1, Day 1, Day 7 and Day 13